Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for FDC
Revenue projections for FDC



Financial Ratios:

currentRatio 3.01100
forwardPE 0.00000
debtToEquity 0.92800
earningsGrowth -0.16200
revenueGrowth 0.06500
grossMargins 0.65074
operatingMargins 0.07811
trailingEps 16.41000
forwardEps 23.30000

FDC's current ratio of 3.011 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. FDC's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
FDC's low earnings and revenue growth point to a possible reduction in profits. This trend suggests that the company may face difficulties in maintaining its profitability and could be a cause for concern among investors.
FDC's negative gross and operating margins signal that the company is not profitable, struggling to cover costs associated with production and operations. This could be a red flag for its financial performance moving forward.
FDC's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Recommendation changes over time:

Recommendations trend for FDC
Recommendations trend for FDC


FDC has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view FDC as a reliable choice for their money, offering a promising avenue for future growth and financial gains.